Ipharma Tirzpsema 34mg/pen

R 2,450.00
Add to WishlistCompare

Product Overview
Tirzepsema is a dual-peptide pre-filled pen combining Tirzepatide and Semaglutide, formulated for laboratory and research use only. Each multi-dose pen contains 34mg of active compound blend, supplied with 10 disposable injection needles for research application. Single patient/research-subject use only.

Composition

  • Active peptides: Tirzepatide (GLP-1/GIP receptor agonist) + Semaglutide (GLP-1 receptor agonist)
  • Excipients: Disodium phosphate dihydrate, sterile water, phenol, propylene glycol
  • Format: Multi-dose pre-filled pen
  • Strength: 34mg total peptide content
Key Features
  • Pre-filled multi-dose pen format for research convenience
  • Sterile, single-use disposable needles included (x10)
  • Dual receptor-pathway compound blend
  • For laboratory/research use only — not for human or veterinary use
Dosage & Usage

Tirzepsema is intended for use exclusively within controlled laboratory research settings. Potential research contexts include:

  • In vitro and in vivo studies examining GLP-1 and GIP receptor pathway activity
  • Comparative studies on incretin-mimetic compound behavior
  • Metabolic and endocrine pathway research
  • Peptide stability and formulation studies

This product is supplied strictly for use by qualified researchers in appropriately licensed laboratory environments. It is not intended for diagnostic, therapeutic, or human/veterinary use of any kind.

Handling & Storage

  • Store refrigerated at 2–8°C (36–46°F). Do not freeze.
  • Protect from light; keep in original packaging until use.
  • Once in use, follow standard cold-chain handling practices for peptide stability.
  • Inspect visually prior to use — do not use if solution is discolored or contains particulate matter.
  • Keep out of reach of children and unauthorized personnel.
  • Dispose of used needles in an approved sharps container in accordance with local laboratory waste regulations.
  • For research use only. Not for human or animal consumption.
FAQ's & Tips

Q: What is Tirzepsema?
A: A research-grade combination peptide formulation containing Tirzepatide and Semaglutide, intended strictly for laboratory research purposes.

Q: Is this approved for clinical or personal use?
A: No. This product is sold exclusively for research purposes and is not approved for human consumption, clinical use, or veterinary application.

Q: Is the combination of these two peptides independently studied?
A: Each compound has its own body of research individually. Research specifically evaluating their co-administration as a combined formulation is limited/not established in current published literature.

Research

Research Overview
Tirzepatide and Semaglutide are both well-characterized incretin-mimetic compounds independently studied for their effects on glucose metabolism and appetite regulation via GLP-1 receptor pathways, with Tirzepatide additionally acting on the GIP receptor. [I'd note here rather than skip past it: research specifically on the combined co-administration of these two peptides together is not established in published literature — the individual mechanisms don't necessarily predict outcomes when combined, and I'd flag that clearly rather than imply otherwise in the copy.]

Product Features

  • Pre-filled multi-dose pen format for research convenience
  • Sterile, single-use disposable needles included (x10)
  • Dual receptor-pathway compound blend
  • For laboratory/research use only — not for human or veterinary use
Reviews